Polymorphic light eruption (PLE) is a common skin disorder that affects millions of people worldwide. It is an inflammatory skin condition that is triggered by exposure to ultraviolet (UV) light, such as sunlight, and is characterized by an itchy, red rash that appears on the skin. While the exact cause of PLE is unknown, it is believed to be related to an abnormal response of the immune system to UV light. This article will explore the causes and treatments of PLE, in order to help doctors better understand and manage this condition.
Polymorphic light eruption (PLE) is a skin disorder that is characterized by an itchy, red rash that appears on the skin after exposure to ultraviolet (UV) light, such as sunlight. The rash typically appears within minutes to hours after exposure to UV light and can last for several days. The rash may be accompanied by other symptoms, such as itching, burning, stinging, and swelling. In some cases, the rash may be accompanied by fever, chills, and fatigue.
The exact cause of PLE is unknown, but it is believed to be related to an abnormal response of the immune system to UV light. It is thought that the body’s immune system mistakenly identifies UV light as a foreign invader and releases chemicals to fight it, resulting in an inflammatory reaction. This reaction causes the skin to become red, itchy, and inflamed.
Anyone can develop PLE, but it is more common in people with fair skin, especially those with a history of sunburns. Other risk factors include a family history of PLE, a history of other skin conditions, and certain medications, such as antibiotics, that can make the skin more sensitive to UV light.
Diagnosing PLE can be difficult, as the condition can resemble other skin conditions. A doctor may ask about the patient’s medical history and perform a physical examination of the skin. In some cases, a skin biopsy may be necessary to confirm the diagnosis.
The primary treatment for PLE is to avoid exposure to UV light. This can be accomplished by wearing protective clothing, such as long-sleeved shirts and wide-brimmed hats, and by using sunscreen with an SPF of at least 30. In addition, certain medications may be prescribed to reduce inflammation and itching. These medications include topical corticosteroids, oral antihistamines, and phototherapy.
Polymorphic light eruption (PLE) is a common skin disorder that is triggered by exposure to ultraviolet (UV) light. While the exact cause of PLE is unknown, it is believed to be related to an abnormal response of the immune system to UV light. Diagnosing PLE can be difficult, as the condition can resemble other skin conditions. The primary treatment for PLE is to avoid exposure to UV light and to use certain medications to reduce inflammation and itching. By understanding the causes and treatments of PLE, doctors can better manage this condition.
1.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
2.
How artificial intelligence could significantly improve the prognosis for cancer patients.
3.
Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.
4.
Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.
5.
Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.
1.
Understanding Neutrophilia: Causes, Symptoms, and Treatment Options
2.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
3.
A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology
4.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
5.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation